NDATOPICALAEROSOL, FOAM
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
LEXETTE (halobetasol propionate) by Design Pharmaceuticals is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown. Approved for psoriasis. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXETTE is a topical aerosol foam formulation of halobetasol propionate, a potent corticosteroid approved in 2018 for treating plaque psoriasis. It works by modulating immune function, inflammation signaling, and protein regulation, though its precise mechanism in psoriasis remains incompletely understood. The foam delivery system offers a novel topical route compared to traditional creams or ointments.
$0.085MPart D
Peak11.1 years to LOEProduct is at peak maturity with modest Part D penetration; commercial teams face margin pressure from branded competitors with higher spending.
Mechanism of Action
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.
Indications (1)
Clinical Trials (1)
Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis
Started Nov 2020
22 enrolled
Palmoplantar PsoriasisPlaque Psoriasis
Career Relevance
Working on LEXETTE offers exposure to a stable, peak-lifecycle topical dermatology product with modest commercial infrastructure at Design Pharmaceuticals. Career growth is constrained by market saturation and approaching LOE; opportunities are best suited for professionals seeking defensive brand management, market access problem-solving, or territory-based sales roles rather than innovation-focused advancement.
Worked on LEXETTE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.